SEC Filing Summary: Bioptix, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bioptix, Inc. (formerly Venaxis, Inc.) on December 12, 2016. The report details the effective implementation of a corporate name change and the commencement of trading under a new ticker symbol on the Nasdaq Capital Market.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure regarding corporate identity and does not contain financial performance data.
Material Changes
- Name Change: Effective November 30, 2016, the company changed its name from "Venaxis, Inc." to "Bioptix, Inc."
- Trading Symbol: Effective December 12, 2016, common stock began trading on the Nasdaq Capital Market under the new symbol "BIOP".
- CUSIP Number: The company was assigned a new CUSIP number: 09074N101.
Outlook, Risks, and Unusual Items
The filing contains no management commentary on future guidance, risks, or contingencies. The only operational note concerns shareholders holding certificated stock: replacement certificates are not mandatory, but shareholders may request new certificates reflecting the new name and symbol through the transfer agent, Corporate Stock Transfer, Inc.
Key Facts for Investor Verification
- Verify the new ticker symbol BIOP on the Nasdaq Capital Market.
- Confirm the new CUSIP number 09074N101 for trade settlement purposes.
- Review the attached press release (Exhibit 99.1) for the official announcement details.
- Note that existing stock certificates remain valid without immediate replacement.